MF
MCID: MYC006
MIFTS: 66

Mycosis Fungoides (MF) malady

Categories: Rare diseases, Cancer diseases, Skin diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mycosis Fungoides

Aliases & Descriptions for Mycosis Fungoides:

Name: Mycosis Fungoides 54 38 12 50 25 52 42 14 69
Alibert-Bazin Syndrome 50 25
Granuloma Fungoides 50 25
Mycosis Fungoides, Unspecified Site, Extranodal and Solid Organ Sites 12
Mycosis Fungoides of Unspecified Site 12
Mycosis Fungoides, Alibert-Bazin Type 56
Mycosis Fungoides Lymphoma 12
Classic Mycosis Fungoides 56
Mycosis Fungoides Nos 12
Mf 12

Characteristics:

Orphanet epidemiological data:

56
classic mycosis fungoides
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

OMIM 54 254400
Disease Ontology 12 DOID:8691
ICD10 33 C84.0 C84.00
ICD9CM 35 202.1
MeSH 42 D009182
NCIt 47 C3246
Orphanet 56 ORPHA2584
ICD10 via Orphanet 34 C84.0
UMLS 69 C0026948

Summaries for Mycosis Fungoides

NIH Rare Diseases : 50 mycosis fungoides is a disease in which t-cell lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. this condition is one of the most common types of t-cell lymphoma. mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. the rash may last for months or years without causing any symptoms. over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin. finally, tumors form which may develop into ulcers and become infected. mycosis fungoides is difficult to cure. treatment is usually palliative, with the intention of relieving symptoms and improving the quality of life. last updated: 1/26/2011

MalaCards based summary : Mycosis Fungoides, also known as alibert-bazin syndrome, is related to folliculotropic mycosis fungoides and marfan syndrome, and has symptoms including pruritus, edema and dry skin. An important gene associated with Mycosis Fungoides is TNFRSF1B (TNF Receptor Superfamily Member 1B), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abraxane and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and lung, and related phenotypes are hematopoietic system and immune system

Genetics Home Reference : 25 Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.

OMIM : 54 Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert... (254400) more...

Wikipedia : 71 Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Related Diseases for Mycosis Fungoides

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
id Related Disease Score Top Affiliating Genes
1 folliculotropic mycosis fungoides 12.4
2 marfan syndrome 11.7
3 cutaneous t cell lymphoma 11.5
4 sezary's disease 11.0
5 monofixation syndrome 10.9
6 shprintzen-goldberg syndrome 10.9
7 neonatal marfan syndrome 10.8
8 lymphoma 10.8
9 microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma 10.8
10 homocystinuria, b6-responsive and nonresponsive types 10.8
11 localized pagetoid reticulosis 10.6
12 granulomatous slack skin disease 10.6
13 parapsoriasis 10.5
14 follicular mucinosis 10.4
15 lymphomatoid papulosis 10.4
16 glycogen storage disease due to glucose-6-phosphatase deficiency 10.4 CCR3 CXCR3
17 renal hypertension 10.4 CCL17 CXCR3 IL5
18 plummer vinson syndrome 10.4 CD7 TNFRSF8
19 venezuelan hemorrhagic fever 10.4 CCL17 CXCR3 IL2
20 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.3 CCL22 IL2 IL5
21 middle lobe syndrome 10.3 CCL17 CCL22 IL5
22 cyclosporiasis 10.3 CXCR3 IL2 IL2RA
23 indian plum allergy 10.3 CCL17 CCL22 IL5
24 smooth muscle tumor 10.3 CXCR3 IL2RA IL5
25 childhood malignant mesenchymoma 10.3 CCL17 CCL22 IL5
26 squamous cell papilloma of skin 10.3 CD7 IL2 IL2RA
27 wilkes stevenson syndrome 10.3 IL2 IL2RA IL5
28 causalgia 10.3 CXCR3 IL2 IL2RA
29 tracheitis 10.3 CCL17 IL2 IL5
30 balkan nephropathy 10.3 CCL17 CXCR3 IL5
31 radial hypoplasia, triphalangeal thumbs and hypospadias 10.3 CXCR3 IL5 ITGB2
32 cerebral sarcoidosis 10.3 IL2 IL2RA STAT3
33 leukemia 10.3
34 retinal ischemia 10.3 CXCR3 IL2 IL2RA
35 inclusion conjunctivitis 10.3 IL2 IL5 TNFRSF1B
36 parasitic protozoa infectious disease 10.3 CCL17 CXCR3 IL5
37 acute dacryoadenitis 10.3 IFNA1 IL2 IL5
38 birth defects 10.3 CCL17 IFNA1 IL2RA IL5
39 epidermolysis bullosa 10.3 CCL17 CCL22 CXCR3 IL5
40 abnormal retinal correspondence 10.3 CTLA4 IL2 IL5
41 anterior foramen magnum meningioma 10.3 IFNA1 IFNA2 IL2 IL2RA
42 pleoconial myopathy with salt craving 10.3 CD7 TNFRSF8
43 alcoholic liver cirrhosis 10.2 CD7 IL2 IL2RA TNFRSF8
44 dermatitis 10.2
45 benign eccrine breast spiradenoma 10.2 CCL22 CXCR3 STAT3
46 mansonelliasis 10.2 CTLA4 IL2 IL5
47 pityriasis lichenoides 10.2
48 deafness, autosomal recessive 67 10.2 CXCL9 CXCR3 IL2RA TNFRSF1B
49 granuloma annulare 10.2
50 psoriasis 10.2

Graphical network of the top 20 diseases related to Mycosis Fungoides:



Diseases related to Mycosis Fungoides

Symptoms & Phenotypes for Mycosis Fungoides

Symptoms by clinical synopsis from OMIM:

254400

Clinical features from OMIM:

254400

Human phenotypes related to Mycosis Fungoides:

56 32 (show all 23)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 56 32 Very frequent (99-80%) HP:0000989
2 edema 56 32 Occasional (29-5%) HP:0000969
3 dry skin 56 32 Very frequent (99-80%) HP:0000958
4 splenomegaly 56 32 Occasional (29-5%) HP:0001744
5 hepatomegaly 56 32 Occasional (29-5%) HP:0002240
6 abnormality of the nail 56 32 Occasional (29-5%) HP:0001597
7 hyperkeratosis 56 32 Occasional (29-5%) HP:0000962
8 skin ulcer 56 32 Occasional (29-5%) HP:0200042
9 hypopigmented skin patches 56 32 Frequent (79-30%) HP:0001053
10 abnormality of the eyelid 56 32 Occasional (29-5%) HP:0000492
11 irregular hyperpigmentation 56 32 Frequent (79-30%) HP:0007400
12 neoplasm of the skin 56 32 Very frequent (99-80%) HP:0008069
13 erythema 56 32 Very frequent (99-80%) HP:0010783
14 skin rash 56 32 Very frequent (99-80%) HP:0000988
15 alopecia 56 32 Frequent (79-30%) HP:0001596
16 eczema 56 32 Very frequent (99-80%) HP:0000964
17 lymphoma 56 32 Very frequent (99-80%) HP:0002665
18 lymphadenopathy 56 32 Frequent (79-30%) HP:0002716
19 abnormality of bone marrow cell morphology 56 32 Occasional (29-5%) HP:0005561
20 skin plaque 56 32 Very frequent (99-80%) HP:0200035
21 poikiloderma 56 32 Frequent (79-30%) HP:0001029
22 abnormality of lymphocytes 56 32 Very frequent (99-80%) HP:0004332
23 cutaneous t-cell lymphoma 56 32 Frequent (79-30%) HP:0012192

MGI Mouse Phenotypes related to Mycosis Fungoides:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 TNFRSF1B TNFRSF8 CCL17 CCR3 CD28 CD7
2 immune system MP:0005387 10.06 CCL17 CCR3 CD28 CD7 CDKN2B CTLA4
3 endocrine/exocrine gland MP:0005379 9.97 CD28 CD7 CDKN2B CTLA4 IL2 IL2RA
4 digestive/alimentary MP:0005381 9.91 IL2 IL2RA IL5 STAT3 TNFRSF1B CD28
5 neoplasm MP:0002006 9.5 IL2 IL5 STAT3 TNFRSF1B CD28 CDKN2B
6 respiratory system MP:0005388 9.23 CCR3 CTLA4 CXCR3 IL2 IL2RA IL5

Drugs & Therapeutics for Mycosis Fungoides

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene Approved October 2012

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
2
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 153559-49-0 82146
3
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1 298-81-7 4114
4
Denileukin diftitox Approved, Investigational Phase 4,Phase 2 173146-27-5
5
Vorinostat Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 149647-78-9 5311
6
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
8 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
20 interferons Phase 4,Phase 2,Phase 1,Early Phase 1
21 Histone Deacetylase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
23 Interferon-alpha Phase 4,Phase 2
24 Clorazepate Dipotassium Phase 4
25 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 1 23214-92-8 31703
28
Etoposide Approved Phase 2, Phase 3, Phase 1, Early Phase 1 33419-42-0 36462
29
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
31
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
32
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
33
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
34
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
35
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
36
Ofloxacin Approved Phase 3 82419-36-1 4583
37
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
38
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
39
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
40
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
41
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
42
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
43
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
44
Morphine Approved, Investigational Phase 3 57-27-2 5288826
45
Captopril Approved Phase 3 62571-86-2 44093
46
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
47
Fluconazole Approved Phase 3 86386-73-4 3365
48
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
49
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
50
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283

Interventional clinical trials:

(show top 50) (show all 374)
id Name Status NCT ID Phase
1 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4
2 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4
3 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4
4 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4
5 Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Recruiting NCT02323659 Phase 4
6 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4
7 Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study Withdrawn NCT01801670 Phase 4
8 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
10 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
11 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Completed NCT00425555 Phase 2, Phase 3
12 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma Completed NCT00490776 Phase 2, Phase 3
13 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
14 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
15 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
16 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
18 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
19 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
20 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
21 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
22 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
23 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
24 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
25 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
26 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
27 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
28 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
29 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With Mycosis Fungoides (MF) Form of CTCL Recruiting NCT02811783 Phase 3
30 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Recruiting NCT02448381 Phase 3
31 PUVA Maintenance Therapy in Mycosis Fungoides Active, not recruiting NCT01686594 Phase 3
32 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Active, not recruiting NCT01578499 Phase 3
33 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
34 Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome Terminated NCT00127881 Phase 3
35 Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides Terminated NCT00056056 Phase 3
36 Lenalidomide Maintenance Post-debulking in Advanced CTCL Terminated NCT01098656 Phase 3
37 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3
38 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
39 Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma Withdrawn NCT01386398 Phase 3
40 Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2
41 Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides Unknown status NCT00002557 Phase 2
42 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
43 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
44 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
45 Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma Unknown status NCT00030589 Phase 2
46 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2
47 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
48 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
49 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
50 Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides Completed NCT00168064 Phase 2

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mycosis Fungoides cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: mycosis fungoides

Genetic Tests for Mycosis Fungoides

Anatomical Context for Mycosis Fungoides

MalaCards organs/tissues related to Mycosis Fungoides:

39
T Cells, Skin, Lung, B Cells, Bone, Breast, Pancreas

Publications for Mycosis Fungoides

Articles related to Mycosis Fungoides:

(show top 50) (show all 930)
id Title Authors Year
1
Computed Tomography scanning in mycosis fungoides - optimising the balance between benefit and harm. ( 28498608 )
2017
2
Ultraviolet A1 Phototherapy in the Treatment of Early Mycosis Fungoides. ( 28441652 )
2017
3
CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides. ( 28441377 )
2017
4
Interstitial Mycosis Fungoides: Setting the Record Straight. ( 27984240 )
2017
5
Oral and Cutaneous Lymphomas other than Mycosis Fungoides and SAczary Syndrome in a Mexican Cohort: Recategorization and Evaluation of International Geographical Disparities. ( 28400635 )
2017
6
ALK Expression is a Rare Finding in Mycosis Fungoides. ( 28426485 )
2017
7
Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. ( 28497585 )
2017
8
Transformation of Mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. ( 28533196 )
2017
9
CD30-positive lymphoproliferative Erkrankung bei einem Patienten mit follikulotroper Mycosis fungoides. ( 28485861 )
2017
10
The role of macrophages in the pathogenesis of mycosis fungoides. ( 28436576 )
2017
11
Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). ( 28466385 )
2017
12
Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. ( 28516243 )
2017
13
Mycosis Fungoides in Pediatric Patients: A Diagnostic Challenge. ( 28473054 )
2017
14
No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach. ( 28448099 )
2017
15
Maintenance phase in PUVA phototherapy of early stage mycosis fungoides. A critically appraised topic. ( 28078669 )
2017
16
Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome. ( 28423383 )
2017
17
Hypopigmented Mycosis Fungoides: Clinical, Histological, and Immunohistochemical Remission Induced by Narrow-band Ultraviolet B. ( 28400643 )
2017
18
Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices. ( 28504404 )
2017
19
Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man. ( 28512405 )
2017
20
Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. ( 28054376 )
2017
21
Scalp-sparing total skin electron therapy in mycosis fungoides: Case report featuring a technique without lead. ( 28438420 )
2017
22
Periorbital Involvement in Early Stage Mycosis Fungoides. ( 28421231 )
2017
23
Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides. ( 28083948 )
2017
24
Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor. ( 28073814 )
2017
25
Mycosis fungoides mimicking tinea pedis. ( 27799613 )
2016
26
The cellular microenvironment and neoplastic population in mycosis fungoides skin lesions: a clinicopathological correlation. ( 27545221 )
2016
27
Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and SAczary syndrome. ( 27104864 )
2016
28
Immunophenotypic shift from CD4(+) to CD8(+) in mycosis fungoides. ( 27167533 )
2016
29
Aberrant microRNA expression in tumor mycosis fungoides. ( 27623940 )
2016
30
Pityriasis Lichenoides-like Mycosis Fungoides: Clinical and Histologic Features and Response to Phototherapy. ( 27746631 )
2016
31
Gelling Your Dermatology Nursing Practice: A Practical Guide for Managing the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel. ( 28529678 )
2016
32
Mycosis fungoides staged by 18F-flurodeoxyglucose positron emission tomography/computed tomography: Case report and review of literature. ( 27828842 )
2016
33
Clinicopathologic Variants of Mycosis Fungoides. ( 27871620 )
2016
34
Leser-TrAclat Sign in Tumor-Stage Mycosis Fungoides. ( 27617461 )
2016
35
A new molecular paradigm in mycosis fungoides and SAczary syndrome. ( 28024703 )
2016
36
Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor. ( 27022231 )
2016
37
Biopsy correlation of surface area vs single axis measurements on CT scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sezary syndrome. ( 28012157 )
2016
38
Photo-sensitive mycosis fungoides: a new variant? ( 27869099 )
2016
39
Prognostic indicators for mycosis fungoides in a Greek population. ( 27552962 )
2016
40
Mycosis Fungoides Associated with Kaposi's Sarcoma, T-cell Rich B-cell Lymphoma, and T-cell Lymphoma with Angioimmunoblastic Features. ( 27663924 )
2016
41
Folliculotropic Mycosis Fungoides in an Adolescent: A Rare Case. ( 27512205 )
2016
42
Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides. ( 27994839 )
2016
43
Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature. ( 27741114 )
2016
44
Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome. ( 27617516 )
2016
45
Keratoderma-like T cell dyscrasia: A report of 13 cases and its distinction from mycosis fungoides palmaris et plantaris. ( 27140811 )
2016
46
Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides. ( 27868149 )
2016
47
Risk of Acute Myocardial Infarction or Stroke in Patients with Mycosis Fungoides and Parapsoriasis. ( 26576854 )
2016
48
Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. ( 28074163 )
2016
49
Latest insights into pathogenesis of mycosis fungoides/cutaneous T-cell lymphoma. ( 27982549 )
2016
50
Clinical Staging and Prognostic Factors in Folliculotropic Mycosis Fungoides. ( 27276223 )
2016

Variations for Mycosis Fungoides

Cosmic variations for Mycosis Fungoides:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM532 KRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,cutaneous T cell lymphoma c.38G>A p.G13D 6

Expression for Mycosis Fungoides

Search GEO for disease gene expression data for Mycosis Fungoides.

Pathways for Mycosis Fungoides

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 38)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 CCL22 CD28 CTLA4 IFNA1 IFNA2 IL2
2
Show member pathways
13.78 CCL17 CCL22 CCR3 CD28 CDKN2B CXCL9
3
Show member pathways
13.53 CCL17 CCL22 IFNA1 IFNA2 IL2 IL2RA
4
Show member pathways
13.44 CCL17 CCL22 CCR3 CD28 CXCL9 CXCR3
5
Show member pathways
13.39 CCL17 CCL22 CCR3 CXCL9 CXCR3 ITGAE
6
Show member pathways
13.36 CCL22 IFNA1 IFNA2 IL2 IL2RA IL5
7
Show member pathways
13.26 CCL17 CCL22 CCR3 CD28 CXCL9 CXCR3
8
Show member pathways
12.86 CCL17 CCL22 CCR3 CXCL9 CXCR3 STAT3
9
Show member pathways
12.8 CD28 CTLA4 CXCL9 IFNA1 IFNA2 IL2
10
Show member pathways
12.77 CD28 IFNA1 IFNA2 IL2 IL2RA STAT3
11
Show member pathways
12.61 CCL17 CCL22 CCR3 CD28 CXCL9 CXCR3
12
Show member pathways
12.57 CD28 IL2 IL2RA IL5 STAT3
13 12.55 CTLA4 IFNA1 IL2 IL2RA ITGB2 STAT3
14
Show member pathways
12.39 CD28 CTLA4 IL2 IL5
15 12.38 CDKN2B IL2 IL2RA ITGB2
16
Show member pathways
12.34 CD28 CTLA4 IL2 IL2RA
17
Show member pathways
12.24 IFNA1 IFNA2 IL2 IL2RA IL5 STAT3
18
Show member pathways
12.13 IFNA1 IFNA2 IL2 IL5
19
Show member pathways
12.06 CCL17 CCL22 CCR3 CXCL9 CXCR3
20 12.02 CCR3 CD28 IFNA2 IL2 IL2RA IL5
21
Show member pathways
12.01 IL2 IL2RA IL5 STAT3
22 11.95 CCL22 ITGB2 STAT3 TNFRSF1B
23 11.84 CD7 IL2RA IL5
24 11.8 CD28 CTLA4 ITGB2
25
Show member pathways
11.77 CTLA4 IL2 IL2RA IL5
26 11.72 IFNA2 IL2 ITGAE
27 11.72 IFNA1 IFNA2 IL2 IL2RA STAT3
28 11.7 CD7 CXCR3 IL2 IL2RA IL5 ITGAE
29 11.6 CD28 CTLA4 TNFRSF8
30 11.51 CCL22 STAT3 TNFRSF1B
31 11.48 CD28 CTLA4 IL2RA IL5 ITGAE ITGB2
32
Show member pathways
11.41 IL2 IL2RA TNFRSF1B
33 11.32 CXCL9 CXCR3 ITGB2
34 11.28 CD28 IL2 IL2RA STAT3
35 11.28 CD28 IL2 IL2RA IL5 TNFRSF1B
36 11.27 CD28 CTLA4 IL2
37 11.2 CCL17 CCL22 CXCL9 IL2 IL5
38 11.1 CCL17 CCL22 CD28 IL2 IL2RA IL5

GO Terms for Mycosis Fungoides

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.1 CD28 CTLA4 CXCL9 CXCR3 IL2RA ITGAE
2 protein complex involved in cell adhesion GO:0098636 8.96 CD28 CTLA4

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.97 CXCR3 IFNA2 IL2RA ITGB2 TIA1 TNFRSF1B
2 adaptive immune response GO:0002250 9.81 CD7 CTLA4 IFNA1 IL2
3 cell surface receptor signaling pathway GO:0007166 9.77 CD28 CXCR3 IFNA2 IL2RA TNFRSF1B
4 negative regulation of inflammatory response GO:0050728 9.75 IL2 IL2RA TNFRSF1B
5 apoptotic signaling pathway GO:0097190 9.74 CD28 TNFRSF1B TNFRSF8
6 cytokine-mediated signaling pathway GO:0019221 9.73 IFNA1 IFNA2 IL5 STAT3
7 cell-cell signaling GO:0007267 9.73 CCL17 CCL22 CXCL9 IFNA2 IL2 ITGB2
8 chemotaxis GO:0006935 9.72 CCL17 CCL22 CCR3 CXCL9 CXCR3
9 neutrophil chemotaxis GO:0030593 9.71 CCL17 CCL22 ITGB2
10 positive regulation of T cell proliferation GO:0042102 9.7 CD28 IL2 IL2RA
11 immune response GO:0006955 9.7 CCL17 CCL22 CD28 CD7 CTLA4 CXCL9
12 humoral immune response GO:0006959 9.65 CD28 IFNA1 IFNA2
13 negative regulation of immune response GO:0050777 9.59 CTLA4 IL2RA
14 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL5
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.56 CD28 IL2
16 T cell chemotaxis GO:0010818 9.55 CXCL9 CXCR3
17 chemokine-mediated signaling pathway GO:0070098 9.55 CCL17 CCL22 CCR3 CXCL9 CXCR3
18 negative regulation of lymphocyte proliferation GO:0050672 9.46 IL2 IL2RA
19 regulation of T cell homeostatic proliferation GO:0046013 9.4 IL2 IL2RA
20 inflammatory response GO:0006954 9.4 CCL17 CCL22 CCR3 CXCL9 CXCR3 IFNA2

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL17 CCL22 CXCL9 IFNA1 IFNA2 IL2
2 type I interferon receptor binding GO:0005132 9.16 IFNA1 IFNA2
3 chemokine activity GO:0008009 9.13 CCL17 CCL22 CXCL9

Sources for Mycosis Fungoides

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....